Myovant Sciences Ltd (NASDAQ:MYOV) has earned an average rating of “Buy” from the seven brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $20.00.
Several brokerages recently weighed in on MYOV. Cowen and Company restated a “buy” rating on shares of Myovant Sciences in a research note on Tuesday, October 3rd. Zacks Investment Research upgraded Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. Evercore ISI began coverage on Myovant Sciences in a research note on Wednesday, August 16th. They set an “outperform” rating on the stock. JMP Securities restated an “outperform” rating and set a $25.00 target price (up from $23.00) on shares of Myovant Sciences in a research note on Wednesday, October 4th. Finally, Robert W. Baird reiterated a “buy” rating and set a $20.00 price target on shares of Myovant Sciences in a research note on Wednesday, October 4th.
Myovant Sciences (NASDAQ:MYOV) traded up 5.67% during midday trading on Thursday, hitting $13.97. The stock had a trading volume of 51,246 shares. Myovant Sciences has a 52-week low of $9.92 and a 52-week high of $18.85. The company’s 50 day moving average price is $13.94 and its 200-day moving average price is $13.94. The stock’s market cap is $849.99 million.
A number of institutional investors have recently modified their holdings of MYOV. Quantitative Systematic Strategies LLC purchased a new position in Myovant Sciences in the second quarter worth approximately $165,000. Goldman Sachs Group Inc. purchased a new position in shares of Myovant Sciences during the second quarter worth $174,000. Wells Fargo & Company MN boosted its position in shares of Myovant Sciences by 331.9% during the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after buying an additional 12,700 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Myovant Sciences by 36.3% during the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock worth $279,000 after buying an additional 6,330 shares during the period. Finally, Swiss National Bank purchased a new position in shares of Myovant Sciences during the second quarter worth $294,000.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
What are top analysts saying about Myovant Sciences Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Myovant Sciences Ltd and related companies.